Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Research Progress of DCLK1 Inhibitors as Cancer Therapeutics

12 Jul 2021

Abstract excerpt

Doublecortin-like kinase 1 (DCLK1) has emerged over the last decade as a unique stem cell marker within gastrointestinal tissues. Evidence from mouse models shows that high Dclk1 expression denotes a population of cells that promote tissue regeneration and serve as potential cancer stem cells. Moreover, since certain DCLK1 isoforms are overexpressed in many cancers and not normal cells, targeting the expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Genomics and Diagnostics
Share to Caveolin-1 and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34254905
DOI: 10.2174/0929867328666210709110721

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Research Progress of DCLK1 Inhibitors as Cancer TherapeuticsPMID 34254905Read ↗

Pleiotropic effects of DCLK1 in cancer and cancer stem cellsSemantic proximity Read ↗

Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1Semantic proximity Read ↗

The kinase activity of the cancer stem cell marker DCLK1 drives gastric cancer progression by reprogramming the stromal tumor landscapeSemantic proximity Read ↗

Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem–like Cells Marked by DCLK1 KinaseSemantic proximity Read ↗

Biochemical and Structural Insights into Doublecortin-like Kinase Domain 1.Semantic proximity Read ↗

DCLK1 induces a pro-tumorigenic phenotype to drive gastric cancer progression.Semantic proximity Read ↗

DCLK1 promotes colorectal cancer stemness and aggressiveness via the XRCC5/COX2 axisSemantic proximity Read ↗

Alternative splice variants of DCLK1 mark cancer stem cells, promote self‐renewal and drug‐resistance, and can be targeted to inhibit tumorigenesis in kidney cancerSemantic proximity Read ↗

Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells.Semantic proximity Read ↗

Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.Semantic proximity Read ↗

Doublecotin-like kinase 1 increases chemoresistance of colorectal cancer cells through the anti-apoptosis pathwaySemantic proximity Read ↗

DCLK1 Regulates Tumor Stemness and Cisplatin Resistance in Non-small Cell Lung Cancer via ABCD-Member-4Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.